Cadence raises $100M to deploy AI agents in chronic care

Digital health company Cadence has closed a $100 million funding round to expand its chronic disease management platform and deploy artificial intelligence agents to automate clinical work, even as its core business model faces mounting regulatory pressure.

Spark Capital led the Series C round, which values the company at $1.23 billion. Cadence currently manages over 100,000 patients with conditions including hypertension, diabetes, and heart failure across more than 20 health system partners.

Why it matters

Cadence's pivot to AI-driven care comes at a critical juncture for remote patient monitoring companies. Federal watchdogs and major insurers are questioning whether monthly reimbursement models genuinely improve care quality or simply create opportunities for billing abuse. If Cadence can demonstrate that regulated AI agents deliver better outcomes than human-staffed monitoring, it could reshape how chronic conditions are managed at scale — and potentially address cost concerns that threaten the entire remote monitoring sector.

Automation under regulatory review

The company is currently in discussions with the FDA about incorporating AI agents into its hypertension management program. CEO and founder Chris Altchek said the goal is to "take it to the next level" by automating portions of the work currently performed by hundreds of human clinicians who monitor patients using connected devices like blood pressure cuffs.

The automation push represents a fundamental shift in how Cadence operates. Rather than relying primarily on clinical staff to review patient data and intervene when needed, the company plans to deploy AI systems that can handle routine monitoring and potentially make care decisions within a regulated framework.

Business model under pressure

Cadence's existing approach — charging insurers monthly fees for remote patient monitoring — has attracted criticism from both the Department of Health and Human Services' Office of Inspector General and major payers including UnitedHealthcare. Critics contend the reimbursement structure incentivizes enrollment volume over care quality and lacks sufficient safeguards against abuse.

These concerns have created uncertainty for Cadence and similar companies that built their businesses around remote monitoring codes. The new capital infusion gives Cadence runway to prove its AI-enhanced model can deliver measurably better outcomes, potentially addressing quality concerns while maintaining financial viability.

The path forward

Cadence's FDA discussions signal the company recognizes it needs regulatory validation for AI-driven care decisions, not just monitoring. How the agency approaches oversight of autonomous AI agents in chronic disease management could set precedents for the broader digital health industry.

The company's ability to scale beyond 100,000 patients while reducing reliance on human clinicians will test whether AI can genuinely transform chronic care economics or simply automate a contested billing model.

These details were first reported by Mario Aguilar at STAT.